The Prognostic Value of Serum and Immunohistochemical Tumour Markers in Advanced Gastric Cancer

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 63-68

  Webb, A ^b   Scott Mackie, P ^b   Cunningham, D ^b   Norman, A ^b   Andreyev, J ^b   O'Brien, M ^b   Bensted, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Alphafeto protein; C erbB 2; CA125; CA19 9; Carcinoembryonic antigen; Chemotherapy; Gastric cancer; Prognostic significance; Tumour markers; human chorionic gonadotrophin

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; TISSUE LEVEL;

ADENOCARCINOMA; ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0029968029     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00504-8     Document Type: Article

References (44)

1. HMSO. Cancer Statistics: Registrations. England and Wales 1987. HMSO, 1993.
2. HMSO. Mortality Statistics: Cause. England and Wales 1991. HMSO, in press.
3. Wittekind Ch, Wachner R, Henke W, et al. Localisation of CEA, HCG, lysozyme, alpha-1-antitrypsin, and alpha-1-antichymotrypsin in gastric cancer and prognosis. Virchows Arch (A) 1986, 409, 715-724.
4. Ito H, Tahara H. Human chorionic gonadotropin in human gastric carcinoma: a retrospective immunohistochemical study. Acta Pathol Jpn 1983, 33, 287-296.
5. Tomita K, Kuwajima M. Chorionic gonadotropin in gastric cancer tissue, especially its relation to the patients prognosis. Jpn J Cancer Clin 1981, 27, 1281-1282 (in Japanese).
6. Mizutani T, Onda M, Tokunaga A, et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993, 72, 2083-2088.
7. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of C-erbB-2 protein in gastric cancer. Cancer 1993, 72, 3179-3184.
8. Yonemura Y, Ninomiya I, Ohoyama S, et al. Immunoreactivity for C-erbB-2 protein is an independent indicator of poor short term prognosis in patients with gastric carcinoma. Cancer 1991, 67, 2914-2918.
9. Paik S, Hazan R, Risher E, et al. Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of C-erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8, 103-112.
10. Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine. Historical perspectives, pitfalls and projections. Cancer 1978, 42, 1399-1405.
11. Carcinoembryonic antigen: its role as a marker in the management of cancer. A National Institutes of Health Consensus Development Conference. Ann Int Med 1981, 94, 407-409.
12. Beatty JD, Romero C, Brown PW, et al. Clinical value of carcinoembryonic antigen. Diagnosis, prognosis and follow up of patients with cancer. Arch Surg 1979, 114, 563-567.
13. Cooper MJ, Mackie CR, Skinner DB, et al. A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. Br J Surg 1979, 66, 120-123.
14. Kuusela P, Haglund C, Roberts PJ, et al. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer 1987, 55, 673-676.
15. Beatty JD, Romero C, Brown PW, et al. Clinical value of carcinoembryonic antigen. Arch Surg 1979, 114, 563-567.
16. Dittrich C, Jakesz R, Havelec L, et al. Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. Cancer Detection and Prevention 1985, 8, 181-187.
17. Sakamoto K, Haga Y, Yoshimura R, et al. Comparative effectiveness of the tumour diagnostics, CA19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987, 28, 323-329.
18. Wobbes T, Thomas CMG, Segers MFG, et al. Evaluation of seven tumour markers (CA50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer 1992, 69, 2036-2041.
19. Tamada R, Hiramoto Y, Tsujitani S, et al. Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy. Jpn J Surg 1985, 15, 23-29.
20. Bates SE, Longo DL. Use of serum tumour markers in cancer diagnosis and management. Semin Oncol 1987, 14, 102-138.
21. Bloomer JR, Waldmann TA, McIntire KR, et al. α-Fetoprotein in non-neoplastic hepatic disorders. JAMA 1975, 233, 38-41.
22. Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer 1974, 34, 1510-1515.
23. Chen DS, Sung JL. Serum alphafetoprotein in hepatocellular carcinoma. Cancer 1977, 40, 779-783.
24. McIntire KR, Waldmann TA, Moertel CG, et al. Serum α-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res 1975, 35, 991-996.
25. Takahashi Y, Mai M, Ogino T, et al. Clinicopathological study of AFP producing gastric cancer significance of AFP in gastric cancer. 1987, 88, 696-700.
26. Braunstein GD, Vaitukaitis JL, Carbone PP, et al. Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med 1973, 78, 39-45.
27. Elliott TE, Moertel CG, Wieand HS, et al. A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 1990, 65, 1491-1494.
28. Gailani S, Chu TM, Nussbaum A, et al. Human chorionic gonadotrophins (hCG) in non-trophoblastic neoplasms. Cancer 1976, 38, 1684-1686.
29. Rosen SW, Weintraub BD, Vaitukaitis JL, et al. Placental proteins and their subunits as tumour markers. Ann Intern Med 1975, 82, 71-83.
30. Yakeishi Y, Mori M, Enjoji M, et al. Distribution of β-human chorionic gonadotropin-positive cells in noncancerous gastric mucosa and in malignant gastric tumours. Cancer 1990, 66, 695-701.
31. Manabe T, Adachi M, Hirao K. Human chorionic gonadotrophin in normal, inflammatory and carcinomatous gastric tissue. Gastroenterology 1985, 89, 1319-1325.
32. Fukayama M, Hayashi Y, Koike M. Human chorionic gonadotropin in gastric carcinoma: an immunohistochemical study suggesting independent regulation of subunits. Virchows Arch (A) 1987, 411, 205-212.
33. Canney PA, Moore M, Wilkinson PM, et al. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984, 50, 765-769.
34. Haga Y, Sakamoto K, Egami H, et al. Clinical significance of serum CA125 values in patients with cancers of the digestive system. Am J Med Sci 1986, 292, 30-34.
35. Jaquinto G, Taccone W, Guarino A, et al. Multiparametric tumour marker (CA19 9, TPA, CA125, CEA) analyses of sera in gastric diseases. Dig Dis Sci New Series 1985, 31, 35.
36. Gupta MK, Arciaga R, Bocci L, et al. Measurement of a monoclonal antibody defined antigen (CA19-9) in the sera of patients with malignant and non-malignant diseases. Cancer 1985, 56, 277-283.
37. Ritts RE, Del Villano B, Go VLW, et al. Initial clinical evaluation of an immunoradiometric assay for CA19-9 using the NCI serum bank. Int J Cancer 1984, 33, 339-345.
38. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker CA19-9 with α-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984, 37, 218-222.
39. Berger MS, Locher GW, Sauere S, et al. Correlation of C-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988, 48, 1238-1243.
40. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
41. Wright C, Angus B, Nicholson S, et al. Expression of C-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989, 49, 2087-2090.
42. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene coamplification units: hst-1/int-2 and C-erbB-2/ ear-1. Cancer Res 1989, 49, 3104-3108.
43. Jain S, Filipe MI, Gullick WJ, et al. C-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991, 48, 668-671.
44. Ohguri T, Sato Y, Koizumi W, et al. An immunohistochemical study of C-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the C-erbB-2 protein really a prognostic indicator? Int J Cancer 1993, 53, 75-79.